

## Drug Monograph

Drug/Drug     **Aranesp™ (darbepoetin alfa) solution for injection /**  
 Class:         **Hematopoietic Agents**  
 Prepared for: MO HealthNet  
 Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Aranesp™ is now available in a single-dose prefilled syringe containing 10 mcg of darbepoetin alfa per 0.4 mL.

**Manufacturer:** Amgen Inc., Thousand Oaks, CA 91320

**Indications:** Aranesp™ is indicated for the treatment of anemia due to chronic kidney disease, including patients on dialysis and patients not on dialysis. It is also indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.

**Costs:** \$71.66 per 0.4 mL syringe of Aranesp™. Maximum Allowable Cost

**Summary of Findings:** This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

**Status Recommendation:**

<input type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
<input type="checkbox"/> Fiscal Edit	<input checked="" type="checkbox"/> PDL

**Type of PA Criteria:**

<input type="checkbox"/> Increased Risk of ADE	<input checked="" type="checkbox"/> Under Solicitation
<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Preferred Agent

Prepared By: Luke Boehmer Pharm.D.  
 Date: August 3, 2015